The Combined use of Metformin and Adalimumab in Iraqi Psoriatic Patients

Main Article Content

Ghadah Ali Al-Oudah, Mohammed M. Mohammed, Mustafa G. Al-Abbassi, Zahraa Hasan Zaboon, Ali Ameer Al-Ameedee

Abstract

  Psoriasis is a complicated, chronic, immune-mediated inflammatory skin disease with a hereditary basis. It is possible that metformin treatment may modulate the function of immune cells, subsequently preventing proliferation of keratinocytes KCs.


 Objective: The present study attempts to find out if the addition of Metformin to biological therapy Adalimumab has the beneficial effect to relieve inflammation in moderate to severe Iraqi psoriatic patients.


Subjects and Methods: The experimental group comprises 30 patients suffering from moderate to severe psoriasis, that were randomly allocated into two groups; Group A: consist of 15 psoriatic patients treated with 40mg of Adalimumab twice monthly for 12 weeks, while Group B: contains of15 psoriatic patients treated with 40mg of Adalimumab twice monthly and a single daily dose of 850mg of metformin for 12 weeks. The psoriasis area and severity index (PASI) was used to assess the percentage improvement changes after treatment period, furthermore, serum levels for inflammatory markers, IL-17 and TNF-α were used to determine their levels by using ELISA technique before and after therapy.


Results: The two groups showed significantly decrease (p<0.05) after treatment when compared with patients before treatments but high significantly decrease in mean IL-17 level and TNF (p<0.05) after treatment with group B in which addition metformin to biological therapy .As well as to that using combination adjuvant therapy in group B result in further improvement as reported by 76 % PIC for PASI score in compared with 60% PIC after 12 weeks of treatment


Conclusion: This study demonstrates that adding a single daily dose of metformin to biological therapy has a more beneficial effect to relieve inflammation of skin associated with psoriasis   

Article Details

How to Cite
Ghadah Ali Al-Oudah, Mohammed M. Mohammed, Mustafa G. Al-Abbassi, Zahraa Hasan Zaboon, Ali Ameer Al-Ameedee. (2023). The Combined use of Metformin and Adalimumab in Iraqi Psoriatic Patients. Journal for ReAttach Therapy and Developmental Diversities, 6(2s), 292–296. Retrieved from https://jrtdd.com/index.php/journal/article/view/295
Section
Articles